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Introduction
Epithelial–mesenchymal transition (EMT) is a major pheno-
typic change characterized by the loss of epithelial features, 
including apicobasal polarity and intercellular contacts, and by 
the gain of mesenchymal properties, such as head–tail polar-
ity, increased contractility, and accumulation of extracellular 
matrix proteins (Lee et al., 2006; Xu et al., 2009). EMT plays 
a key physiological role in embryonic development and wound 
healing (Nakaya and Sheng, 2008) and has been identified as 
a central mechanism in various pathological processes includ-
ing carcinogenesis (Klymkowsky and Savagner, 2009) and tis-
sue fibrosis (Kalluri and Neilson, 2003). Importantly, EMT can 
progress further along a myogenic program, leading to the gen-
eration of myofibroblasts (MFs), which is hallmarked by the 
expression of –smooth muscle actin (SMA). In this study, we 
will use the term epithelial–MF transition (EMyT) to indicate 
this myogenic form of EMT. Tissue accumulation of MFs and 
the level of SMA expression show strong correlation with the 
severity of fibrosis (Yang and Liu, 2001). Moreover, studies in 
genetically tagged mice indicated that a substantial portion of 
MFs originates from the epithelium in various models of lung 
and kidney fibrosis, suggesting an important role for EMyT 
in the disease process (Iwano et al., 2002; Kim et al., 2006).   
Despite  the  key  significance  of  EMyT  in  the  pathology  of 
fibrosis, the molecular mechanisms that turn on and regulate 
the myogenic program (SMA expression) in the epithelium are   
incompletely understood.
  E
pithelial–myofibroblast  (MF)  transition  (EMyT)  is 
a  critical  process  in  organ  fibrosis,  leading  to   
–smooth muscle actin (SMA) expression in the epi-
thelium. The mechanism underlying the activation of this 
myogenic program is unknown. We have shown previ-
ously that both injury to intercellular contacts and trans-
forming growth factor  (TGF-) are indispensable for 
SMA expression (two-hit model) and that contact disrup-
tion induces nuclear translocation of myocardin-related 
transcription factor (MRTF). Because the SMA promoter 
harbors both MRTF-responsive CC(A/T)-rich GG element 
(CArG)  boxes  and  TGF-–responsive  Smad-binding   
elements, we hypothesized that the myogenic program is 
mobilized by a synergy between MRTF and Smad3. In 
this study, we show that the synergy between injury and 
TGF- exclusively requires CArG elements. Surprisingly, 
Smad3 inhibits MRTF-driven activation of the SMA pro-
moter, and Smad3 silencing renders injury sufficient to in-
duce SMA expression. Furthermore, Smad3 is degraded 
under two-hit conditions, thereby liberating the myogenic 
program. Thus, Smad3 is a critical timer/delayer of MF 
commitment in the epithelium, and EMyT can be dissected 
into Smad3-promoted (mesenchymal) and Smad3-inhibited 
(myogenic) phases.
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Surprisingly, we found that the CArG boxes are neces-
sary and sufficient for the synergy between contact injury and 
TGF- in SMA promoter activation, that Smad3 is a strong 
inhibitor of MRTF-driven SMA expression, and that Smad3 is 
degraded during EMyT. These results suggest a novel regulatory 
mechanism in myogenic reprogramming and define a Smad3- 
promoted and a Smad3-inhibited phase in EMyT.
Results
MRTF plays a critical role in cytoskeletal 
reprogramming during EMyT
Our previous studies have established that both the disruption 
of intercellular contacts (by LCM) and exposure to TGF- are 
required for EMyT in tubular cells. To determine the impor-
tance of MRTF in the expression of SMA in the context of this 
two-hit model, we transfected cells with control or MRTF-
specific siRNA and treated them with LCM and TGF- simul-
taneously for 48 h. We used two specific siRNA constructs, 
both of which provided a near-complete knockdown of MRTF 
(Fig. 1 A and Fig. S1). As expected (Masszi et al., 2004), 
in  the  presence  of  nonrelated  (NR)  siRNA,  the  combined 
treatment  induced  robust  SMA  expression.  This  response 
was abolished by the MRTF siRNAs. To assess whether the 
observed  inhibitory  effect  is  restricted  to  SMA  expression 
or other CArG box–containing genes might also be affected, 
we checked the fate of some important representatives of the 
CArGome (Sun et al., 2006). Similar to SMA, filamin, SRF,   
the myosin heavy chain, and to a lesser extent, CapZ and   
1-integrin, were up-regulated during EMyT, and these responses 
were strongly inhibited by the suppression of MRTF (Fig. 1 A 
and Fig. S1). The down-regulation of MRTF strongly reduced 
cofilin expression under both resting and stimulated condi-
tions. These findings imply that MRTF is a master regulator 
of actin skeleton–related genes and thereby the cytoskeletal 
reprogramming during EMyT.
Stimulatory effect of both inputs converge 
on the CArG boxes
Next, we sought to identify the critical promoter elements 
responsible for the effect of LCM, TGF-, and their syn-
ergy. The proximal portion of the SMA promoter contains 
several regulatory elements, including two CArG boxes, two 
SBEs, and a TGF- control element (TCE; Fig. 1 B). As 
earlier studies performed by us and others have shown that 
LCM activates the Rho pathway (Fan et al., 2007; Busche 
et al., 2008), we hypothesized that LCM might primarily 
act via CArG boxes, whereas the effect of TGF- might be 
predominantly mediated by SBEs and/or TCE. To character-
ize the importance of these elements, we generated a set of 
luciferase reporter constructs with various mutations of the 
SMA promoter (Fig. 1 B). The cells were transfected with 
wild-type (WT) or mutant SMA promoter plasmids along 
with  the  internal  control  plasmid,  pRL-TK,  and  treated 
with TGF- and/or LCM for 24 h (Fig. 1 C). In agreement 
with our previous results (Masszi et al., 2004; Fan et al., 
2007),  both  TGF-  and  contact  injury  induced  a  modest 
Increasing evidence indicates that EMT is a result of 
multiple, simultaneous inputs (Masszi et al., 2004; Kim et al., 
2009a,b). Our previous experiments aimed at the identifica-
tion of critical triggering factors showed that both an injury 
of intercellular contacts (e.g., their uncoupling by low cal-
cium medium [LCM] or wounding) and TGF-1 (TGF-) are 
required to induce SMA expression in kidney epithelial cells 
(Masszi et al., 2004). Therefore, these data defined a two-hit 
model of EMyT, which is particularly suitable to dissect the 
key cellular events underlying MF differentiation. We then 
addressed  the  mechanism  whereby  contact  injury  impacts 
SMA expression and identified myocardin-related transcrip-
tion factor (MRTF), a recently described myogenic transcrip-
tional coactivator (Wang et al., 2002), as a key mediator of 
the process (Fan et al., 2007; Sebe et al., 2008). The proximal 
part of the SMA promoter contains two CC(A/T)-rich GG ele-
ment (CArG) boxes, which are cis-elements targeted by serum 
response factor (SRF), a major regulator of cell growth and 
myogenic differentiation (Hautmann et al., 1999; Miano et al., 
2007). The recent discovery of the myocardin family (myo-
cardin, MRTF-A, and -B; Wang et al., 2001; Miralles et al., 
2003) explained the old enigma of how SRF could fulfill these 
separate (growth promoting and myogenic) roles: binding of 
myocardin proteins confers muscle specificity to and enhances 
the activity of SRF. Moreover, MRTF, a major inducer of cyto-
skeletal genes, is itself regulated by the cytoskeleton. Accord-
ing to the current model, in quiescent cells, MRTF is bound to 
G-actin in the cytosol, but upon actin polymerization, it dis-
sociates from G-actin and translocates to the nucleus (Posern 
and Treisman, 2006). We and others observed that disassem-
bly of cell contacts in epithelial monolayers (e.g., by LCM) 
provokes robust nuclear translocation of MRTF in a Rho/Rho 
kinase– and Rac-dependent manner (Fan et al., 2007; Busche 
et al., 2008; Sebe et al., 2008). Importantly, MRTF is nec-
essary for SMA expression during EMyT (Fan et al., 2007; 
Elberg et al., 2008). Nonetheless, injury-induced MRTF trans-
location alone is insufficient for SMA expression, as the pro-
cess also requires TGF-.
What is the mechanism whereby TGF- synergizes with 
contact injury to induce myogenic reprogramming? We con-
sidered that signaling through receptor Smads (R-Smads), the 
direct targets of the activated TGF- receptor kinase, might 
account for the synergy. This idea stems from the facts that   
(a)  R-Smads  mediate  a  variety  of  the  fibrogenic  effects  of 
TGF- (Xu et al., 2009), (b) the SMA promoter harbors Smad-
binding elements (SBEs), which specifically bind Smad3 (Hu 
et al., 2003), and (c) Smad3 has been shown to directly bind 
to MRTF (Morita et al., 2007a). Cognizant of this scenario, 
we hypothesized that MRTF translocation and Smad3 signal-
ing represent the contact injury– and TGF-–dependent arms 
of the two-hit scheme. We considered that MRTF and Smad3 
target their cognate cis-elements in the SMA promoter inde-
pendently, but their effect might be more than additive. Alter-
natively, Smad3 might directly bind to MRTF, and the complex 
synergistically drives the promoter either through CArGs or 
SBEs. We also asked whether TGF- signaling modifies the 
nucleocytoplasmic traffic of MRTF.385 Epithelial–myofibroblast transition • Masszi et al.
TGF- prolongs the injury-induced nuclear 
accumulation of MRTF
Having seen that the effect of the two hits converges on CArG 
boxes,  we  wished  to  determine  how  these  stimuli  impact  the 
nucleocytoplasmic transport of MRTF. We asked whether their 
synergy might be explained by their concerted effect on MRTF 
localization. To address this, we used both immunofluorescence 
microscopy (Fig. 2, A and B) and Western blotting of nuclear 
extracts (Fig. 2, C and D). The two approaches gave similar results: 
in untreated cells within intact, confluent monolayers, MRTF was 
cytosolic. LCM, when applied alone, induced rapid (30 min) and 
robust  nuclear  translocation  of  MRTF  (Fig.  2).  However,  this 
response was transient, as at 2 h, there was a major reduction in 
the number of cells with nuclear MRTF (Fig. 2, A and B) and in 
the overall nuclear MRTF content (Fig. 2, C and D). Thereafter, 
MRTF remained at this slightly suprabasal level. TGF- alone did 
not induce any translocation of MRTF in the first 2 h, and even   
after 6 h caused only a moderate translocation in a small fraction 
(10%) of the cells. This is in agreement with our pervious data 
showing that TGF- in itself is unable to induce SMA expres-
sion in confluent monolayers (Fan et al., 2007). Importantly, the 
inability of TGF- to elicit MRTF translocation was not caused by 
general unresponsiveness: TGF- provoked strong nuclear trans-
location and phosphorylation of Smad3 (Fig. 2 E). Furthermore, 
when TGF- was added together with LCM, both the number 
increase in the promoter activity (2.6- and 4-fold, respec-
tively),  whereas  the  combined  treatment  acted  synergisti-
cally (13-fold). First, we investigated the role of the genuine 
TGF-–responsive regions, namely the two SBE and TCE 
sites. Interestingly, inactivating mutations of these elements 
alone or in combination neither inhibited the effect of the 
individual treatments nor affected their synergy. Moreover, 
promoter constructs harboring mutation in the TCE exhib-
ited significantly higher activation than the WT when the 
cells  were  challenged  with  LCM  or  the  combined  treat-
ment. In contrast, inactivation of the CArG sites strongly   
reduced the effect of all treatments. Mutation of the CArG-A   
box  had  a  strong  although  incomplete  inhibitory  effect, 
whereas  the  CArG-B  and  double  mutants  were  rendered 
entirely unresponsive to LCM, TGF-, or their combination 
(Fig. 1 C). A short, 152-bp promoter segment, which con-
tains the two intact CArG boxes but lacks SBE1 and the E 
boxes, remained sensitive to both stimuli (Fig. 1 C, inset). 
Together, these findings indicate that the CArG boxes are 
necessary  and  sufficient  not  only  for  the  contact  injury–
induced (Rho/Rho kinase–mediated; Fan et al., 2007; Sebe   
et  al.,  2008)  activation  of  the  promoter  but  also  for  the   
TGF-–triggered response and synergy between these stim-
uli. In contrast, all of the genuine TGF- elements (SBE and 
TCE) are dispensable.
Figure 1.  MRTF is a key transcription fac-
tor  for  CArG-dependent  genes  in  EMyT.  
(A)  Confluent  LLC-PK1  cells  transfected  with 
NR () or MRTF siRNA (+) for 24 h were serum   
deprived  for  3  h  and  treated  with  normal 
medium (control) or the combination of LCM 
and 10 ng/ml TGF- (LCM + TGF-) for 48 h   
followed by Western blotting for the indicated 
proteins. (B) The applied SMA promoter lucif-
erase  constructs.  (C)  The  CArG  boxes  are 
critical,  whereas  genuine  TGF-–responsive 
elements are dispensable for the effect of in-
dividual stimuli and their synergy on the SMA 
promoter.  Near-confluent  monolayers  were 
transfected with the indicated SMA constructs 
and renilla luciferase pRL-TK plasmid for 24 h 
and either left untreated or exposed to LCM, 
TGF-, or the combination of these (black col-
umns) for another 24 h. (inset) Activation of 
the 152-bp SMA promoter that contains only 
the CArGs and TCE. The firefly/renilla ratio of 
the control was taken as 1. Error bars indicate 
mean ± SEM.JCB • VOLUME 188 • NUMBER 3 • 2010   386
Given the facts that (a) LCM and TGF- induce the nuclear 
translocation of MRTF and Smad3, respectively, (b) these fac-
tors can interact, and (c) the SMA-inducing effects are mediated 
via CArGs, we hypothesized that a Smad3–MRTF complex 
might exert an augmented effect on CArG cis-elements. Indeed, 
similar potentiation by Smads through non-SBE sites has been 
described previously in other promoters (Qiu et al., 2003). To 
test whether Smad3 can indeed facilitate the transcriptional   
effect of MRTF, cells were cotransfected with the 765-bp 
(WT) SMA-Luc/renilla reporter system along with constructs 
encoding Flag-tagged MRTF, Myc-tagged Smad3, or both 
(Fig.  3 A). As  expected,  MRTF  robustly  induced  the  SMA 
promoter. Smad3 itself did not affect SMA promoter activity 
(<1.4-fold increase), whereas it strongly stimulated SBE4-
Luc, a Smad3-responsive promoter construct (Fig. 3 B). To 
our surprise, when coexpressed with MRTF, Smad3 potently 
inhibited the MRTF-induced activation of the SMA promoter 
of cells with strong nuclear MRTF translocation and the overall 
nuclear MRTF content was higher than after LCM stimulation 
at the peak, and importantly, it remained significantly above the 
LCM-induced level for the investigated period (24 h). It is note-
worthy that when combined with LCM, TGF- markedly pro-
moted nuclear MRTF accumulation even at times when alone it 
had no effect. These findings show that although TGF- is a very 
weak stimulus to induce MRTF translocation in the intact epithe-
lium, it augments and prolongs the nuclear accumulation of MRTF 
provoked by contact injury. This effect likely contributes to the 
synergy between the combined stimuli and the ensuing EMyT.
Smad3 is a strong inhibitor of  
the SMA-inducing effect of MRTF:  
a surprising finding
Smad3, one of the central mediators of TGF- signaling, has 
been shown to directly bind to MRTF (Morita et al., 2007a). 
Figure 2.  TGF- augments and prolongs the 
injury-induced nuclear accumulation of MRTF. 
(A)  Confluent  monolayers  were  exposed  for 
various times to the indicated stimuli, stained 
for  MRTF,  and  visualized  by  immunofluores-
cence microscopy. Bar, 30 µm. (B) Images were 
quantified as a percentage of cells with clear 
nuclear accumulation of MRTF. (C) Nuclear 
extracts were prepared from cells treated as 
shown. Nuclear MRTF was visualized by West-
ern blotting from extracts containing equal   
(5 µg) protein. Equal loading was verified by 
histones (shown for the LCM condition). WCL, 
whole  cell  lysate.  (D)  Densitometric  quantifi-
cation of C. Values are expressed relative to 
the density of the MRTF signal in 5 µg WCL 
(100%) loaded on the same membrane (n ≥ 3). 
(E) TGF- induces early and robust nuclear 
translocation and phosphorylation of Smad3 
in  confluent  LLC-PK1  cells.  Nuclear  extracts 
were  prepared  from  cells  treated  as  shown 
and  probed  with  total  and  phospho-Smad3 
antibodies. Error bars indicate mean ± SEM.387 Epithelial–myofibroblast transition • Masszi et al.
E boxes) are required for the inhibition (Fig. 3 A). These find-
ings imply that Smad3 interferes with the stimulatory effect of 
MRTF mediated via the CArGs.
Morita et al. (2007a) have reported that MRTF binds to 
the C-terminal but not the N-terminal half of Smad3. To assess 
whether the inhibitory effect of Smad3 might depend on the 
same region, we tested the effects of N- and a C-terminal Smad3 
constructs (Fig. 3 D). The N-terminal half failed to inhibit the 
effect of MRTF, whereas the C-terminal half recapitulated the 
(Fig. 3 A). This effect was specific for Smad3, as overexpres-
sion of Smad2 did not inhibit the SMA promoter (Fig. 3 C). To 
address whether Smad3 might inhibit MRTF by affecting any 
of the two SBEs or the TCE box (i.e., in a CArG-independent 
manner), we used our triple-SMA promoter mutant in which 
these elements are inactivated. Smad3 efficiently suppressed 
the MRTF-induced response of this mutant as well. Further-
more, the same inhibitory effect was observed on the 152-bp 
promoter, indicating that no additional upstream elements (e.g., 
Figure 3.  Smad3 strongly inhibits the MRTF-
induced  stimulation  of  the  SMA  promoter, 
and  this  effect  requires  the  CArG  box  and 
the Smad3 C terminus. (A) Cells were trans-
fected with WT or mutant SMA-Luc and pRL-TK 
constructs  along  with  empty  vector,  MRTF, 
and/or Smad3 for 48 h. (B) Smad3 expres-
sion potently stimulates the SBE4-Luc reporter. 
Cells  were  cotransfected  with  empty  vector 
or  Smad3  and  the  SBE4-Luc/pRL-TK  system.   
(C) Cells were cotransfected with SMA-Luc and 
with empty vector, MRTF, and/or Smad2 for 
48 h. (D) Cells were cotransfected with empty 
vector (none), N-terminal (N-term; 1–210 aa) 
or  C-terminal  (C-term;  211–425  aa)  Smad3 
construct,  the  SMA-Luc/pRL-TK  system,  and 
MRTF or empty vector as indicated. (E) Simi-
lar localization of N- and C-terminal Smad3 
constructs as visualized by immunostaining for 
their Myc tag. Bar, 20 µm. Error bars indicate 
mean ± SEM.JCB • VOLUME 188 • NUMBER 3 • 2010   388
level of Smad3 protein expression under the two-hit conditions 
(Fig. 4 A). Intriguingly, LCM itself induced a 50% reduction in 
Smad3. TGF- alone had marginal effect after 24 h and caused 
a slight decrease after 48 h. When LCM and TGF- were com-
bined, Smad3 expression dropped dramatically, exhibiting 90% 
reduction after 48 h. This effect was selective for Smad3, as the 
level of Smad2 and Smad4 remained unaltered (Fig. 4 B).
To  address  the  mechanisms  responsible  for  decreased 
Smad3  protein,  we  first  measured  the  effects  of  the  two-hit 
scheme on Smad3 mRNA. TGF- significantly reduced Smad3 
mRNA, whereas LCM had only marginal effect. The combined 
treatment led to a 50% reduction after 24 h (Fig. 4 C). Because 
the overall loss in Smad3 protein exceeded this level, we also 
investigated the potential contribution of enhanced protein deg-
radation  using  two  approaches. We  expressed  Flag-Smad3, 
which is driven by an artificial (cytomegalovirus) promoter or 
treated the cells with the protein synthesis inhibitor cyclohexi-
mide and then tested whether the various stimuli could (further) 
reduce Smad3 levels. LCM and the combined treatment (but 
not TGF-) induced strong reduction in Flag-Smad3 protein   
effect  of  the  full-length  protein. This  differential  effect  was 
not the result of distinct nuclear localization of these Smad3 
proteins  because  immunostaining  against  their  Myc  epitope 
revealed that they were similarly expressed and both localized 
in the cytoplasm and the nucleus with nuclear predominance 
(Fig. 3 E).
Next, we verified that Smad3 overexpression does not 
inhibit and in fact facilitates the nuclear translocation/retention   
of MRTF (Fig. S2). Thus, Smad3 may contribute to the pro-
longed nuclear retention of MRTF seen upon TGF- stimula-
tion (Fig. 2, A–D), but it strongly inhibits the promoter-inducing 
effect of MRTF.
Smad3 expression is diminished under 
myogenic (two hit) conditions
Our experiments suggested that Smad3, a central mediator of 
TGF- signaling, might be a negative regulator of the SMA pro-
moter. However, we have also shown that TGF- is necessary 
for SMA expression. To address this apparent discrepancy, we 
investigated the fate of Smad3 during EMyT by measuring the 
Figure  4.  Myogenic  (two  hit)  conditions  in-
duce  dramatic  loss  of  Smad3  and  mitigate 
the  MRTF–Smad3  interaction.  (A)  Cells  were 
treated according to the two-hit scheme for the 
indicated times, and Smad3 expression was 
assessed by Western blotting. (B) Smad3 deg-
radation is selective. The various stimuli were 
applied for 24 h. (C–E) Smad3 is regulated 
at both mRNA and posttranscriptional levels. 
(C) Smad3 mRNA content was determined   
by qPCR after 24 h treatment and normalized 
to GAPDH content and the control sample.   
(D)  Cells  transfected  with  Flag-Smad3  vector 
were treated for 24 h as indicated. Flag-Smad3 
levels were measured by probing for the tag. 
(E)  Cells  were  preincubated  with  5  µg/ml 
cycloheximide  and  treated  as  indicated  for 
12 h. Overall protein loss as a result of the 
inhibition of de novo synthesis was compen-
sated  by  loading  equal  amount  of  protein.   
(F) MRTF–Smad3 association in the two-hit model. 
Cells were treated as indicated for 1 or 24 h   
followed  by  immunoprecipitation  with  anti-
MRTF antibody. Precipitates were probed for 
MRTF  and  the  coprecipitating  Smad3.  (top) 
Densitometric quantification of the cosediment-
ing  Smad3  normalized  to  the  control.  Note 
that long-term combined treatment eliminates 
the  LCM-triggered  increase  in  the  associa-
tion of Smad3 and MRTF. Error bars indicate 
mean ± SEM.389 Epithelial–myofibroblast transition • Masszi et al.
while it provides sufficient MRTF translocation. In control 
cells, LCM induced a 10-fold increase in SMA mRNA after 6 h. 
Down-regulation of Smad3 in the absence of stimulus caused 
a similar increase. Intriguingly, after Smad3 depletion, LCM 
provoked a dramatic rise (2,500-fold over baseline) in SMA 
mRNA, amounting to a 250-fold stimulation compared with the 
effect of Smad3 elimination alone.
To test whether the reduction in Smad3 indeed impacted 
the interaction between MRTF and the endogenous SMA pro-
moter, we used a chromatin immunoprecipitation (ChIP) assay 
(Fig. 5 D). Cells were transfected with control or Smad3 siRNA 
and exposed to normal medium or LCM. MRTF was immu-
noprecipitated, and the precipitates were analyzed with a PCR 
probe against the proximal CArG box of the SMA promoter 
(Elberg et al., 2008). MRTF immunoprecipitates from control 
cells captured some SMA CArG-A element, the level of which 
increased upon LCM treatment. The coprecipitated CArG-A 
signal did not detectably increase by Smad3 elimination alone; 
however, the effect of LCM was much stronger in the Smad3-
depleted cells (Fig. 5 D). Collectively, these findings indicate 
that stimulus-induced or siRNA-provoked reduction in Smad3 
expression facilitates the association between MRTF and the 
CArG-A box of the endogenous SMA promoter, stimulates the 
promoter, and increases SMA mRNA.
Suppression of Smad3 potentiates  
the expression of SMA and other 
CArGome proteins
To investigate whether a reduction in Smad3 indeed translates 
into elevated SMA protein levels, we compared the expression 
of SMA in the presence of control or Smad3 siRNA in cells 
treated according to the two-hit scheme (Fig. 6 A). Although 
in control cells SMA was just becoming detectable after a   
48-h exposure to these stimuli (Masszi et al., 2004), in the 
Smad3 knockdown group, robust SMA expression occurred 
(Fig. 6 A). Moreover, in Smad3 down-regulated cells, LCM 
in itself was sufficient to provoke SMA protein expression. 
Because LCM alone never causes SMA expression in con-
trol cells, this striking observation implies that the absence of 
Smad3 makes TGF- unnecessary for SMA expression and   
renders contact injury, as a single hit, sufficient for MF gen-
eration. Identical results were obtained when another Smad3-
specific siRNA was used (unpublished data). To test whether 
SMA  expression  in  Smad3-depleted  cells  still  remained 
dependent on MRTF, cells were cotransfected with MRTF 
and Smad3 siRNAs. The absence of MRTF prevented SMA 
expression  in  the  Smad3  knockdown  cells  as  well,  when 
LCM or LCM + TGF- were used as stimuli (Fig. 6 A). This 
verifies that the absence of Smad3 did not divert the myo-
genic program to an alternate pathway; instead, it increased 
the  efficiency  of  the  MRTF-dependent  mechanism.  Impor-
tantly, the robust potentiation of SMA expression by the loss 
of Smad3 was also observed in BEAS-2B lung epithelial cells 
and human gingival fibroblasts (Fig. 6 B), implying that this 
is a general phenomenon. Smad2 silencing had no such effect 
(Fig. 6 C). The loss of Smad3 also facilitated the expression 
of cofilin and SRF, suggesting that Smad3 can also inhibit the 
(Fig. 4 D). Moreover, the combined treatment facilitated the loss 
of endogenous Smad3 even in the presence of cycloheximide 
(Fig. 4 E). These results show that myogenic stimuli induce dra-
matic loss in Smad3 protein through both transcriptional and 
posttranscriptional mechanisms, and this process precedes the 
expression of SMA.
Interaction between Smad3 and MRTF in 
the two-hit model
Our  findings  suggest  that  TGF-–enhanced  Smad3  degra-
dation  might  be  an  important  contributor  to  MF  transition 
presumably through the disinhibition of MRTF. To address 
this idea, we first examined whether the association between 
MRTF and Smad3 changes in the context of the two-hit model 
(Fig. 4 F). Under resting conditions, immunoprecipitates of 
endogenous  MRTF  contained  some  endogenous  Smad3. 
Short-term (1 h) stimulation with LCM or the combination, 
but not TGF- alone, increased the association between the 
two proteins. Importantly, in cells treated with LCM alone, the 
association remained high or increased even further after 24 h. 
In contrast, in the presence of LCM and TGF-, the amount 
of coprecipitating Smad3 dropped back to the level found in 
unstimulated cells. The most plausible interpretation of this 
finding is that because of Smad3 degradation, less Smad3 was 
available for binding. Collectively, long-term combined stim-
ulation leads to increased MRTF level in the nucleus without 
increased MRTF–Smad3 association.
Elimination of Smad3 enhances the activity 
of the SMA promoter
So far, we showed that Smad3 overexpression inhibits the effect 
of MRTF and that Smad3 degrades in the two-hit model. In the 
following experiments, we sought to examine whether decreas-
ing Smad3 levels indeed play a role in the genetic reprogram-
ming during EMyT. We first determined whether the level of 
Smad3 degradation, as observed in the two-hit model, corre-
lates with the ensuing SMA promoter activation. To this end, we 
treated the cells according to the two-hit scheme (LCM, TGF-,   
or both) and prepared lysates at various times (2, 6, 12, 24, 
and 48 h) after stimulation. Smad3 expression was determined 
in each sample by Western blotting as in Fig. 4 A. In parallel 
experiments, cells had been transfected with the 765-bp SMA-
Luc reporter and treated as for the Western blots, after which the   
activity of the SMA promoter was measured. Having obtained 
these two datasets, we plotted the activation of the SMA pro-
moter against the level of the corresponding Smad3 expres-
sion (Fig. 5 A). The resulting function was best fitted with a 
hyperbola (see also the linearized form; r
2 = 0.93), signifying a 
reciprocal relationship between the level of Smad3 and the cor-
responding promoter response.
Next, we tested whether reduction in Smad3 is indeed 
the causal factor that permits increased activation of the endog-
enous SMA promoter. Cells were treated with Smad3 siRNA 
(causing 90% reduction in Smad3 expression; Fig. 5 B) and 
challenged with LCM for 3 or 6 h. Subsequently, SMA mRNA 
content was determined by quantitative PCR (qPCR; Fig. 5 C). 
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association between MRTF and Smad3 are indeed critical for 
the Smad3-induced inhibition, we deleted a 7-aa-long region 
(S279–P285) within the B1 box of MRTF-B (B1p; Fig. 7 C). 
This section of the B1 box was selected because Morita et al., 
(2007a) have described that the B1 box is critical for Smad3 bind-
ing; however, it is also essential for the SRF–MRTF association, 
and therefore, B1 is transcriptionally inactive (Zaromytidou 
et al., 2006). To overcome this problem, we eliminated only 
the proximal part of B1, which does not contain the LKYHQYI 
sequence, the critical core for SRF binding (Zaromytidou et al., 
2006). Indeed, B1p retained substantial SMA promoter–inducing 
activity (Fig. 7 D), whereas it exhibited a dramatically reduced 
binding to Smad3 (Fig. 7 C). Importantly, B1p was much less 
sensitive to the inhibitory action of Smad3 than the WT (27 vs. 
78% inhibition; Fig. 7 D). These findings imply that binding of 
Smad3 to MRTF is a critical mechanism in the Smad3-mediated 
inhibition of the SMA promoter (see Discussion).
expression of other CArGome proteins (Fig. 6 D). Finally,   
E-cadherin down-regulation was less robust in Smad3-depleted 
cells (Fig. 6, A and E), a finding consistent with (but less 
pronounced than) that reported by Morita et al. (2007a) in 
MDCK cells. Together, these results indicate that elimination 
of Smad3 strongly stimulates EMyT, or conversely, Smad3 
acts as a break or delayer of MF generation.
Smad3 interferes with the SRF–MRTF 
interaction
To gain insight into the molecular mechanism whereby Smad3 
inhibits the function of MRTF, we asked whether it interferes 
with the MRTF–SRF interaction. To test this, we transfected cells 
with Myc-MRTF and HA-SRF and followed their association 
after silencing (Fig. 7 A) or overexpressing Smad3 (Fig. 7 B). The   
former condition strongly facilitated, whereas the latter mark-
edly reduced the association of SRF with MRTF. To test whether 
Figure  5.  Reduced  Smad3  expression  ro-
bustly facilitates SMA promoter activity, SMA 
mRNA expression, and the interaction between 
MRTF  and  the  endogenous  SMA  promoter. 
(A)  Relative  Smad3  levels  were  determined 
by  Western  blotting  after  LCM  or  combined 
treatment at various times (0–48 h) and plot-
ted against the corresponding SMA promoter 
activity  measured  in  parallel  after  the  same 
treatments.  Each  point  represents  the  means 
of three determinations. Power function fit re-
sulted in a hyperbola. (inset) Linearization of 
the relationship using the reciprocal of the pro-
moter activity. (B) Efficiency of Smad3 silenc-
ing. (C) Smad3 silencing strongly potentiates 
LCM-induced  mRNA  expression.  Cells  were 
treated with NR or Smad3 siRNA and left un-
treated or exposed to LCM for 3 or 6 h and 
processed  for  RNA  extraction.  SMA  mRNA 
was determined by qPCR and normalized to 
GAPDH. Data are expressed as fold change 
(logarithmic  scale)  compared  with  control.   
(D) Smad3 silencing enhances MRTF binding 
to the SMA promoter. Cells were transfected 
as in B, exposed to normal medium or LCM 
for 1 h, and processed for ChIP assays using 
anti-MRTF antibody. (top) Antibody-associated 
SMA  promoter  signals  were  quantified  by 
qPCR (shown as fold cycle threshold change). 
(middle)  Amplicons  shown  on  agarose  gels   
after  30  PCR  cycles  from  the  input  and  the 
MRTF antibody precipitates. (bottom) Western 
blots verifying Smad3 down-regulation. Error 
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TGF- failed to induce SMA mRNA in control cells, whereas it   
had a substantial effect in the absence of Smad3. These data 
indicate that Smad3 is essential for the expression of key pro-
teins of mesenchymal transition, whereas it inhibits the myo-
genic reprogramming.
Because many cytoskeletal genes are regulated by CArG 
boxes, we investigated whether Smad3 down-regulation might 
induce F-actin reorganization toward an MF-like phenotype. 
After Smad3 silencing, many epithelial cells acquired elon-
gated shape, lost their peripheral actin ring, and formed strong 
central stress fibers (Fig. 8 C). In addition, these cells tended to 
migrate away from the edges of clusters and did not form typi-
cal islands with rounded boundaries. Control epithelial cells 
at the periphery of the islands contained few and small focal 
adhesions, which were parallel to the cell edges. In contrast, 
Smad3-depleted cells had many large and more mature focal 
adhesions  (as  detected  by  total  and  phospho-FAK,  paxillin, 
and -actinin staining) that were perpendicular to the irregu-
lar cell edges. Collectively, the loss of Smad3 facilitates MF-
like remodeling of the actin cytoskeleton, but these cells lack 
important features of the mesenchymal transition such as the 
up-regulation of PAI-1 and CTGF.
Opposite roles of Smad3 in the induction 
of mesenchymal and muscle characteristics
Although  our  findings  indicate  a  potent  inhibitory  role  for 
Smad3 in the process of EMyT, Smad3 has been also impli-
cated as a strong profibrotic transcription factor that con-
tributes  to  EMT.  To  explain  this  apparent  discrepancy,  we 
considered that Smad3 might play distinct roles in the first 
(mesenchymal) and second (myogenic) phase of the process. 
To address this, we followed the impact of Smad3 knock-
down  on  the  transcription  of  PAI-1  (plasminogen  activa-
tor  inhibitor-1),  a  TGF-–responsive,  profibrogenic  gene, 
and  SMA,  the  hallmark  of  MFs.  Smad3  silencing  induced 
opposite responses to TGF- in these genes (Fig. 8 A). Both 
the basal level of the PAI-1 mRNA and its TGF-–induced 
rise  were  strongly  suppressed. Accordingly,  Smad3  siRNA 
reduced PAI-1 protein expression induced by TGF- or the 
combined  treatment  (Fig.  8  B).  Similarly,  the  absence  of 
Smad3  prevented  the  LCM/TGF-–induced  up-regulation   
of  connective  tissue  growth  factor  (CTGF),  another  media-
tor of EMT (Fig. 8 B). In contrast, Smad3 silencing resulted 
in a significant increase in SMA mRNA in nonstimulated 
cells, which was further augmented by TGF- (Fig. 8 A).   
Figure 6.  The one-hit scenario. Smad3 silenc-
ing renders injury sufficient to induce MRTF- 
dependent  SMA  expression  and  potentiates 
the expression of other CArG-dependent genes. 
(A) Confluent monolayers were exposed to NR, 
Smad3, MRTF, or Smad3 + MRTF siRNAs for 
24 h followed by 48 h treatment according to 
the two-hit scheme. Cell lysates were prepared 
and probed by Western blotting for the indi-
cated proteins. (B) Human lung epithelial cells 
(BEAS-2B)  and  gingival  primary  fibroblasts   
(HGF)  were  transfected  with  NR  or  Smad3 
siRNA and 24 h later treated with TGF- for 
48  h.  Whole  cell  lysates  were  probed  for   
the  indicated  proteins.  (C)  Smad2  silencing 
does  not  facilitate  SMA  expression.  Cells 
were transfected with siRNA against Smad2 
and treated as in A for 2 d. Whole cell lysates 
were probed. (D) Cells were transfected as in-
dicated and left untreated or exposed to LCM 
and processed for Western blotting using anti-
bodies against cofilin and SRF. (E) E-cadherin 
loss is less complete in Smad3 siRNA cells.   
E-cadherin blots were analyzed by densitom-
etry and normalized to control values. Error 
bars indicate mean ± SEM.JCB • VOLUME 188 • NUMBER 3 • 2010   392
converge on these elements, which are necessary and sufficient 
for the synergy between these inputs. Indeed, inactivation of 
SBEs had no significant effect, whereas disruption of TCE, the 
binding site for Krüppel-like factors, facilitated the activation 
of the promoter, suggesting that these transcriptional regulators 
may have an inhibitory effect (Liu et al., 2005). (2) One of the 
critical mechanisms through which TGF- facilitates MRTF 
signaling and SMA expression is that it reduces the expression 
of Smad3, i.e., a major mediator of its own signaling. Impor-
tantly, our results show that Smad3 is a strong inhibitor of the 
SMA-inducing effect of MRTF (Figs. 3 and 5–8) because (a) an 
inverse relationship exists between endogenous Smad3 expres-
sion and the activation of the SMA promoter, (b) overexpres-
sion of Smad3 abrogates the SMA promoter–stimulating effect 
of MRTF, and (c) down-regulation of Smad3 renders contact 
injury (as a single hit) sufficient to induce SMA expression,   
increases SMA mRNA, and facilitates the binding of MRTF 
to  the  endogenous  SMA  promoter.  In  addition, TGF-  pro-
longs the nuclear accumulation of MRTF (Fig. 2). This may be 
Discussion
MRTF has emerged as an indispensible mediator of actin skel-
eton remodeling and myogenic reprogramming during EMyT 
(Fan et al., 2007; Morita et al., 2007a,b; Elberg et al., 2008). 
Indeed, our current studies indicate that in addition to SMA, 
MRTF is necessary for the increased or sustained expression 
of a whole array of cytoskeletal proteins, the genes of which 
contain CArG boxes in their promoter (Fig. 1). Therefore, it has 
become a central question how MRTF signaling, a primarily 
Rho- and Rac-controlled process (Hill et al., 1995; Miralles 
et al., 2003; Fan et al., 2007; Busche et al., 2008; Sebe et al., 
2008),  collaborates  with  (other)  TGF-–induced  pathways, 
which are also indispensible for EMyT. Our experiments have 
provided two significant and rather surprising insights into this 
mechanism: (1) detailed mutational analysis of the SMA pro-
moter revealed that not only the contact injury–induced MRTF 
translocation but also the TGF-–induced pathways target the 
MRTF–SRF-dependent CArG boxes (Fig. 1). Thus, all effects 
Figure  7.  Smad3  interferes  with  MRTF–SRF 
interaction.  (A)  Cells  were  transfected  with 
Myc-MRTF  and  HA-SRF  along  with  NR  or 
Smad3  siRNA.  Association  of  MRTF  and   
SRF was analyzed by coimmunoprecipitation. 
Smad3 silencing was detected from whole cell 
lysates (WCL). Controls for the immunoprecipi-
tation were reaction without antibody (No AB) 
or  Myc  transfection  (No  Tx).  (right)  Densito-
metric analysis of three experiments is shown. 
(B) Myc-MRTF and HA-SRF were cotransfected   
with empty vector or Smad3. MRTF was immuno-
precipitated  with  anti-Myc  antibody  as  in  A   
from  control  or  LCM-treated  (1  h)  cells.   
(C) A 7-aa sequence in the B1 region is critical 
for Smad3 binding. The SRF-binding core is 
underlined. The predicted Smad3-binding site 
(S279-P285) is shown in italic. (top) This latter 
region was deleted to generate B1p mutant. 
Coimmunoprecipitation  shows  decreased  as-
sociation of Smad3 to B1p compared with 
WT. (D) B1p mutant shows reduced sensitivity 
to inhibition by Smad3. Cells were transfected 
with SMA-Luc, B1p, or WT MRTF along with 
empty vector or Smad3. Luciferase assay was 
performed 48 h later. Results are normalized 
to the control (top; fold increase over control) 
or expressed as a percentage of the maximal 
effect  of  the  given  MRTF  construct  (bottom).   
*, P < 0.05. Error bars indicate mean ± SEM.393 Epithelial–myofibroblast transition • Masszi et al.
Rac activation), whereas the second one is required for MRTF 
activation, e.g., by eliminating an inhibiting factor. In addition, 
the second hit may lengthen the nuclear stay of MRTF. This 
view can also explain individual differences among the applied 
experimental systems: if MRTF is constitutively nuclear (Elberg 
et al., 2008), one hit (TGF-) is likely sufficient. Alternatively, 
in certain cells, TGF- may trigger strong enough Rho and/or 
Rac activation (Bhowmick et al., 2001) and consequent MRTF 
translocation, and thus, it may bring about both requirements. 
However, fully intact epithelia or other confluent cells are rela-
tively insusceptible to the myogenic action of TGF- (Masur 
et al., 1996; Petridou et al., 2000; Masszi et al., 2004; Fan et al., 
2007). This observation has major relevance to real pathologi-
cal conditions and implies that tissue injury, which can activate 
Rho GTPases either by uncoupling intercellular contacts (Fan 
et al., 2007; Samarin et al., 2007; Busche et al., 2008; Sebe et al., 
2008) and/or by integrin stimulation (Chen et al., 2006; Kim 
et al., 2009b), may hugely potentiate the SMA-inducing effect 
of TGF-. This in turn may lead to dysregulated epithelial heal-
ing and excessive MF differentiation.
In skeletal muscle, Smads have been shown to suppress 
myogenesis (Liu et al., 2001; Zhu et al., 2004). Recently, an 
interesting mechanism has been proposed whereby a complex 
caused by additional actin polymerization as well as increased 
Smad3-dependent MRTF retention (Fig. S2). This may predis-
pose the cells to enhanced MRTF-mediated transactivation once 
the decreasing levels of Smad3 liberate MRTF from its inhib-
ited state. As our observations are somewhat unexpected, it is 
important to integrate them into the current knowledge about 
the mechanisms underlying EMT and EMyT.
Regarding the central role of CArGs, our findings are in 
agreement with a recent study (Elberg et al., 2008), which found 
that  both  CArGs  were  necessary  for  TGF-–induced  SMA 
promoter  activation  in  human  renal  tubular  cells.  However, 
an unusual feature of that system, as opposed to other tubular 
(LLC-PK1 [Fan et al., 2007] and MDCK [Morita et al., 2007a]) 
cells is that MRTF was constitutively nuclear, even in unstimu-
lated cells. Nonetheless, TGF- remained necessary to induce 
SMA promoter activation and protein expression, implying that 
an additional (yet unidentified) TGF-–dependent mechanism 
is still necessary even in the presence of nuclear MRTF. We 
propose that the TGF-–induced reduction in Smad3 and the 
consequent disinhibition of MRTF may be such an input for 
MRTF  activation.  Our  findings  also  interpret  the  molecular 
underpinnings of the two-hit scenario: the first hit is neces-
sary for the nuclear translocation of MRTF (e.g., via Rho and 
Figure  8.  Smad3  silencing  has  opposite 
effects  on  the  expression  of  mesenchymal 
marker PAI-1 and on MF characteristics (SMA 
and cytoskeleton remodeling). (A) PAI-1 and 
SMA mRNA was measured by qPCR in con-
trol and Smad3-depleted cells (Fig. 5 C) and 
treated  with  vehicle  or  TGF-  for  3  or  6  h. 
Note that although Smad3 depletion strongly 
stimulates TGF-–induced SMA mRNA expres-
sion,  the  effect  is  still  much  less  (0.125) 
compared with LCM (Fig. 5 C), in accordance 
with the fact that TGF- alone (as opposed to 
LCM) does not induce SMA expression even in 
Smad3-depleted cells. (B) Expression of PAI-1 
and CTGF protein under two-hit condition in 
Smad3-containing  and  -depleted  cells.  Cells 
were  transfected  with  NR  or  Smad3  siRNA 
for 24 h, treated for an additional 48 h as 
indicated, and processed for Western blotting. 
(C) Smad3 depletion induces reorganization 
of the cytoskeleton. Cells were transfected with 
NR (top) or Smad3 siRNA (bottom) for 48 h, 
and F-actin and focal adhesions were visual-
ized by rhodamine phalloidin or staining for 
FAK, phosphorylated FAK (pFAK), paxillin, or 
actinin. Loss of Smad3 induces the formation 
of  central  stress  fibers  and  thick,  elongated   
focal adhesions in cells located at the edges 
of islands. (bottom) Higher magnification im-
ages are shown of boxed areas. Bars: (top) 
30 µm; (bottom) 10 µm. Error bars indicate 
mean ± SEM.JCB • VOLUME 188 • NUMBER 3 • 2010   394
posed  to  promote  its  ubiquitination  and  proteasomal  degra-
dation. Future work should determine the exact mechanisms 
whereby TGF- reduces Smad3 mRNA and LCM promotes   
Smad3 degradation.
The overall role of Smad3 in fibrogenesis and EMT (par-
ticularly in EMyT) is complex and controversial. In this study, 
we  will  consider  the  reported  negative  and  positive  effects. 
Accumulating evidence shows that the progression of fibrosis is 
associated with the down-regulation of R-Smad expression. In 
cellular and animal models of kidney (Poncelet et al., 2007) and 
lung (Zhao and Geverd, 2002) fibrosis (which involve EMT), 
Smad3 levels dropped dramatically, and this process was con-
comitant with SMA expression. Decreased Smad2 levels and 
increased expression of Smad ubiquitination regulatory factor-
2 were reported in animal models and patients with fibrogenic 
nephropathies (Tan et al., 2008). Furthermore, reduced Smad3 
phosphorylation and nuclear translocation were observed during 
MF formation in skin and liver (Dooley et al., 2001; Reisdorf 
et al., 2001). Although these studies showed that the progres-
sion of fibrosis and R-Smad down-regulation occur in parallel, it 
remained unknown whether there is a cause–effect relationship 
between these events. The inhibition of MRTF by Smad3 offers 
a new mechanism that links these phenomena. Other compel-
ling data connecting the loss of R-Smads with EMT come from   
studies on the tumor-promoting action of TGF-. In epithelial 
cells expressing oncogenic mutations of the Raf–MAPK path-
way, TGF- induced EMT and loss of Smad3, whereas the 
reexpression of Smad3 restored the epithelial phenotype (Nicolás 
et al., 2003). Moreover, ablation of Smad2 in keratinocytes pro-
moted EMT and carcinogenesis (Hoot et al., 2008). Considered 
together, these studies and our findings indicate that R-Smads 
can act as negative regulators of EMT or EMyT during fibrosis 
progression or tumorigenesis.
However, substantial literature suggests that R-Smads are 
key mediators in TGF-–induced fibrosis and EMT (Roberts   
et al., 2006). Strong support for this view originates from studies 
using Smad3 knockout mice (Yang et al., 1999), which exhibit 
reduced susceptibility to matrix deposition and EMT in models 
of skin (Flanders et al., 2003), lens (Saika et al., 2004), and kid-
ney fibrosis (Sato et al., 2003). However, two important points 
should be considered. First, much of the protection was attrib-
uted to impaired recruitment of TGF- production by macro-
phages in some (Ashcroft et al., 1999), albeit not all (Lakos 
et al., 2004), fibrosis models in Smad3
/ mice. Second, Smad3 
protein may not be fully eliminated from these animals. They 
harbor an exon 8 deletion, leading to the loss of the last 89 aa 
of Smad3, which leads to a functional null mutant. However, 
the truncated protein may be expressed (at various levels) in 
different tissues (Yang et al., 1999), and it may still interact 
with various partners, as indicated by the fact that it exerts a 
dominant-negative effect. Thus, the mutant may lose its profi-
brogenic but may keep its antifibrogenic potential. Moreover, 
the pathology of two Smad3 knockout mice (with either exon 
2 or 8 deleted) is completely different: the first succumbs to 
intestinal tumors (Zhu et al., 1998) and the other to autoim-
munity (Yang et al., 1999), implying the differential functional 
repertoire of the truncated proteins. Nonetheless, there is no 
between MRTF-A and Smad 1/4 may inhibit skeletal muscle 
differentiation in a CArG-independent manner by inducing the 
expression of the Id3 (inhibitor of differention-3) protein (Iwasaki 
et al., 2008). Id3 is an antagonist of basic helix-loop-helix tran-
scription factors, which target E boxes present in the promoter 
of many muscle genes, including SMA. Although such mecha-
nisms may also operate in the epithelium, the Smad3-mediated 
inhibition of the MRTF-induced activation of the SMA pro-
moter clearly represents a distinct mode of regulation. This is 
evident from our finding that the inhibitory action of Smad3 
against MRTF is manifest in a short promoter construct, which 
does not contain E boxes.
We identified a 7-aa segment within the B1 region of 
MRTF-B, which is critical both for the MRTF–Smad3 binding 
and for the efficient inhibition of the MRTF-triggered SMA pro-
moter by Smad3. The simplest interpretation of our data is that   
direct binding between Smad3 and MRTF inhibits the inter-
action between MRTF and the CArG box–SRF complex (Fig. 9 A).   
Consistent with such mechanism (a), the binding sites for 
Smad3 and SRF on MRTF are adjacent, (b) the MRTF–SRF 
association inversely correlates with Smad3 expression (Fig. 7),   
and (c) Smad3 down-regulation enhances MRTF binding to 
the CArG boxes of the endogenous SMA promoter (Fig. 5).   
A possible additional mechanism invokes that SRF can directly 
bind to Smad3 (Lee et al., 2007), which may also inhibit the 
SRF–MRTF association (Fig. 9).
The interaction of MRTF or myocardin with Smad3 has 
multiple functional consequences. The MRTF–Smad3 complex 
has been implicated in the down-regulation of E-cadherin by 
inducing its negative regulator, Slug, through a nonconventional 
SBE (Morita et al., 2007a). This way, the MRTF–Smad3 com-
plex facilitates the loss of epithelial characteristics, i.e., the first 
phase of EMT. Interestingly, in fibroblasts, Smad3 was found 
to increase the activity of myocardin or SRF on some smooth 
muscle–related  promoters  in  a  CArG-independent  manner 
(Qiu et al., 2005). It remains to be tested whether such an effect 
is specific to myocardin as opposed to MRTF and/or to fibro-
blasts. In any case, our results show that the inhibitory action of 
Smad3 on MRTF-mediated, CArG-dependent SMA transcrip-
tion vastly overrules any potential CArG-independent stimulatory 
effect during EMyT. Finally, SRF binding to Smad3 can also 
antagonize SBE-mediated TGF- effects, e.g., apoptosis (Lee 
et al., 2007). In summary, bilateral and mutually competitive 
interactions between the vertices of the MRTF–Smad3–SRF 
triangle may determine the dominant features and timing of the 
various phases of EMyT (Fig. 9 A). The interaction of MRTF 
with Smad3 may help suppress the epithelial markers, and at the 
same time, it puts SMA expression and MF transition on hold 
by competing with the SRF–MRTF interaction. Once Smad3 is 
degraded, the MRTF–SRF complex will dominate and lead to 
myogenic reprogramming.
We  show  that  both  transcriptional  and  posttranscrip-
tional mechanisms contribute to the two hit–induced reduc-
tion in Smad3 levels (Fig. 4). Consistent with this, TGF- was 
reported to suppress Smad3 mRNA transcription (Yanagisawa   
et al., 1998), whereas phosphorylation of Smad3 in its linker 
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test this idea in the real pathological settings of fibrotic dis-
eases.  This  scenario  may  also  provide  important  insights 
with regards to the potential benefits and problems of anti-
fibrotic therapies aimed at the reduction of Smad3 function 
or expression.
Materials and methods
Reagents
The rabbit polyclonal anti-MRTF (anti-BSAC) antibody was described previ-
ously (Sasazuki et al., 2002). In whole cell lysates of LLC-PK1 cells, this anti-
body visualizes a doublet at 160 kD (Sebe et al., 2008), of which the 
top one is more prominent in nuclear extracts. Commercially available anti-
bodies were used against the following antigens: Flag (clone M2), SMA 
(clone 1A4), -actinin (clone BM-75.2), tubulin (Sigma-Aldrich), cofilin, 
Smad2, phospho-Smad3, Smad4 (Cell Signaling Technology), c-Myc 
(clone 9E10), SRF, CTGF (Santa Cruz Biotechnology, Inc.), GAPDH (EMD), 
histones,  1-integrin,  paxillin  (Millipore),  PAI-1,  Smad3  (Abcam),  FAK, 
zonula occludens-1, phospho-FAK (Invitrogen), E-cadherin and filamin A 
(clone 5/ABP280; BD), HA.11 (clone 16B12; Covance), and CapZ (AbD 
Serotec). Secondary antibodies were obtained from Jackson Immuno-
Research Laboratories. Recombinant human TGF- was obtained from R&D 
Systems. Rhodamine-conjugated phalloidin was obtained from Invitrogen.
Cell culture and treatment
LLC-PK1 (Cl4) cells, a porcine proximal tubular epithelial cell line (provided 
by R.C. Harris, Vanderbilt University School of Medicine, Nashville, TN) 
doubt that Smad3 can suppress epithelial genes (Morita et al., 
2007a) and is essential for the expression of various mesenchy-
mal genes (Massagué et al., 2005). How can these apparently 
disparate views be reconciled? We propose that the solution 
may lie in the dynamics of the process. According to our model 
(Fig. 9 B), EMyT can be divided into a Smad3-dependent (early/
mesenchymal) and -independent (late/myogenic) phase. Smad3 
contributes to the loss of epithelial markers and is critical for 
the  expression  of  mesenchymal  markers  and  certain  matrix 
proteins. It may also prepare the second phase by promoting 
nuclear MRTF accumulation and the synthesis of proteins (e.g., 
ED-A fibronectin) that enhance SMA expression (Isono et al., 
2002). This phase is followed by gradual degradation of Smad3, 
which enables the mobilization of the myogenic program. This 
switch is a prerequisite for the motile and contractile pheno-
type. This interpretation is also consistent with the existence of 
Smad3-independent EMT (Banh et al., 2006). However, in the 
absence of Smad3, the EMT program is diverted to a predomi-
nantly myogenic path.
In summary, we propose that Smad3 is a critical check-
point  protein  or  timer,  which  regulates  (delays)  the  final 
commitment to MF transition. Clearly, future studies should 
Figure 9.  Smad3 is a critical delayer/timer 
of  the  MF  commitment  in  epithelial  cells.  
(A) Potential or tested consequences of various 
bilateral  interactions  among  Smad3,  MRTF, 
and SRF. (B) New model dissecting the process 
of  EMyT  into  a  Smad3-dependent  (early/ 
mesenchymal) and -independent/inhibited (late/ 
myogenic) phase, and the proposed role of the 
Smad3–MRTF interaction or the lack thereof in 
various key events of EMyT.JCB • VOLUME 188 • NUMBER 3 • 2010   396
Luciferase reporter assays
Luciferase reporter assays were performed as described in our previous 
studies (Masszi et al., 2003, 2004). In brief, cells were plated onto 6-well 
plates and at 60% confluence were transfected with the mixture of 0.5 
µg/well luciferase construct, 0.05 µg/well pRL-TK, and 2 µg/well empty 
carrier or expression vector. 16 h later, cells were serum starved for 3 h 
and treated for 24 h if not indicated otherwise. Finally, cells were lysed, 
and luciferase activity was determined using the Dual Luciferase Reporter 
Assay System kit (Promega) and a luminometer (Lumat 9507; Berthold)   
according to the manufacturers’ instructions. For each condition, treatments 
were performed in duplicates, and experiments were repeated at least 
three times. From each sample, the firefly luciferase activity corresponding 
to a specific promoter construct was normalized to the renilla luciferase   
activity of the same sample. Results are expressed as fold changes com-
pared with the mean firefly/renilla ratio of the untreated controls taken 
as a unit.
RNA interference
MRTF siRNAs were generated after obtaining a partial sequence of the 
porcine MRTF gene from LLC-PK1 cells. It is noteworthy that the sequence 
obtained through RT-PCR was highly homologous to MRTF-B but not to 
MRTF-A, suggesting that the former is the predominant and potentially the 
only isoform expressed in these cells. The optimal target sequences (5-AAC-
ATGGAGTGGCTAGACATT-3 and 5-AACAGCAGTGAAGATAGAGAG-3)   
were determined using the siRNA Target Finder program (Applied Bio-
systems). The siRNAs against the pig Smad3 (target sequence 5-AAG-
AGTTCACTCCACATTCTC-3; based on GenBank sequence accession 
no. NM_214137.1) and Smad2 (target sequence 5-AAATACGATAGATCA-
GTGGGA-3;  GenBank  accession  no.  NW_001885794.1)  and  the 
human Smad3 (target sequence 5-AAGGCCATCACCACGCAGAAC-3; 
NM_005902.3) were designed using Target Finder tool (Applied Biosys-
tems). NR control siRNA was purchased from Ambion. LLC-PK1 cells were 
cultured in antibiotic-free growth medium and transfected with 100 nM   
siRNA using Lipofectamine RNAiMAX (Invitrogen). For EMyT induction, 
cells were transfected at 60% confluence. After overnight incubation, cells 
reached complete confluence and were treated with the appropriate condi-
tions of the two-hit model for 48 h.
Western blotting
After treatments, cells were scraped into Triton lysis buffer (30 mM Hepes, 
pH 7.4, 100 mM NaCl, 1 mM EGTA, 20 mM NaF, and 1% Triton X-100) 
supplemented with 1 mM Na3VO4, 1 mM phenylmethylsulphonyl fluor-
ide, and Complete Mini protease inhibitor cocktail (Roche). Protein con-
centration was determined, and samples were denatured by boiling in 
Laemmli sample buffer (Bio-Rad Laboratories). Equal amount of protein 
(10 µg) was subjected to SDS-PAGE and Western blotting as described 
previously (Masszi et al., 2004). Densitometry was performed with a 
densitometer (GS800; Bio-Rad Laboratories) and the Quantity One soft-
ware (Bio-Rad Laboratories).
Protein determination
The protein concentration from nondenatured cell lysates was determined 
using a BCA protein assay (Thermo Fisher Scientific) with a bovine serum 
albumin as standard.
Immunoprecipitation
Cells were grown on 10-cm Petri dishes, and after appropriate treatment, 
lysed in Triton lysis buffer. To remove cell debris, samples were spun at 
12,000 rpm at 4°C for 10 min, and aliquots of samples for whole cell 
lysates were taken. Supernatants (1–2 mg protein) were precleared with 
protein G agarose beads (Thermo Fisher Scientific) and were incubated with 
the appropriate antibody (1 µg/sample). To capture immunocomplexes, 
protein G agarose beads were added to the mixture for 1 h. Subsequently, 
the beads were washed three times with Triton lysis buffer supplemented 
with 1 mM Na3VO4. Captured proteins were eluted into Laemmli sample 
buffer (Bio-Rad Laboratories) and analyzed by Western blotting.
Nuclear extraction
Nuclear  extracts  were  prepared  from  confluent  layers  of  LLC-PK1  cells 
grown on 6-cm dishes using the NE-PER Nuclear Extraction kit (Thermo 
Fisher Scientific) according to the manufacturer’s recommendation. The   
nuclear extracts were collected, their protein concentration was determined, 
and samples of equal protein content (5 µg) were analyzed by Western 
blotting.  Antihistone  antibody  was  used  to  check  for  equal  loading  of   
nuclear proteins.
were cultured in low glucose DME (Invitrogen) supplemented with 10% 
fetal bovine serum and 1% streptomycin/penicillin solution (Invitrogen) at 
37°C in humidified atmosphere (air/CO2 ratio 19:1) as in our previous 
study (Masszi et al., 2003). The cells were incubated under serum-free 
conditions for at least 3 h before various treatments. To induce cell con-
tact disassembly, cells were thoroughly washed with PBS (Invitrogen) and 
cultured in nominally calcium chloride–free DME (LCM; Invitrogen). Such 
treatment resulted in an instant drop in transepithelial resistance measured 
by voltohmmeter and the disruption of cell contacts observed by phase-
contract microscopy in 15 min. Where indicated, cells were treated with 
TGF- (4 ng/ml for biochemical experiments and 10 ng/ml for promoter 
luciferase  assays).  Human  gingival  fibroblasts  (Pender  and  McCulloch, 
1991) were provided by C. McCulloch (University of Toronto, Toronto, 
Ontario, Canada), and BEAS-2B were purchased from American Type 
Culture Collection.
Plasmids and transient transfection
The p765-SMA-Luc reporter construct containing the proximal 765-bp por-
tion of the rat SMA promoter in a pGL3-basic vector (WT), the constructs 
harboring inactivating mutation at the SBE1 or SBE2 sites (SBE1mut and 
SBE2mut;  Hu  et  al.,  2003),  and  the  p152-SMA-Luc  reporter  construct 
with the 152-bp-long SMA promoter piece were provided by S.H. Phan 
(University  of  Michigan  Medical  School,  Ann  Arbor,  MI).  To  generate 
additional (or combined) mutations in certain cis-regulatory elements, 
PCR-based mutagenesis was performed. The mutations (in parentheses) 
and the corresponding primer pairs were as follows: to inactivate SBE1 
(C
524/T,  A
525/C,  and  C
528/A),  5-TACAGACTTCATTGATACTACA-
CAAAGCTTCCAGACTACATAC-3 and 5-GTATGTAGTCTGGAAGCTTT-
GTGTAGTATCAATGAAGTCT-3;  to  mutate  SBE2  (C
+15/T,  A
+16/G,  and 
G
+17/C), 5-CCACCCACCTGCAGTGGAGAAGCCCAGC-3 and 5-CTG-
GGCTTCTCCACTGCAGGTGGGTGGT-3 (Hu et al., 2003); to mutate TCE 
(T
53/C, G
52/T, and G
50/C), 5-TGGGAAGCGAGCTGCAGGGGAT-
CAGACCA-3 and 5-TGGTCTGATCCCCTGCAGCTCGCTTCCCA-3 (Hu 
et al., 2007); to inactivate CArG-A (C
71/A, C
70/A, G
63/A, and G
62/A),   
5-CAGCCTGTCTTTGCTAATTGTTTAAGAAGCGAGTGGGAGG-3 and   
5-CCTCCCACTCGCTTCTTAAACAATTAGCAAAGACAGGCTG-3;  and   
to mutate CArG-B (C
121/A, C
120/A, G
113/A, and G
112/A), 5-GTT-
TTGTGCTGAGGTAACTATATAATTGTGTTAGAGTGAACG-3  and  5-CGT-
TCACTCTAACACAATTATATAGTTACCTCAGCACAAAAC-3  (Shimizu   
et al., 1995).
These mutations were shown to effectively block the function of the 
corresponding cis-elements: binding of Smad3 to the mutated SBE1 or 
SBE2 (Hu et al., 2003) was abolished, and the TCE lost its transcriptional 
activity (Hu et al., 2007). The Smad3-responsive reporter construct SBE4-
Luc was provided by A.B. Roberts (National Institutes of Health, Bethesda, 
MD). The thymidine kinase minimal promoter-driven renilla luciferase inter-
nal control plasmid, pRL-TK, was purchased from Promega. The N-terminally 
Myc-tagged human Smad2 and the N-terminally Myc- or Flag-tagged 
Smad3 expression constructs (all in pCMV5B backbone) were provided 
by  L.  Attisano  (University  of  Toronto).  From  the  Myc-Smad3  construct,   
N- (aa 1–210) and C-terminal (aa 211–405) expression constructs were 
generated. The Flag-tagged MRTF-B plasmid was provided by E.N. Olson 
(University of Texas Southwestern Medical Center, Dallas, TX). Expression 
of this construct in LLC-PK1 cells gives two Flag-positive bands at 160 and 
110 kD. C-terminally Myc-tagged MRTF-B was generated by using the 
Flag- tagged MRTF-B as the template, and the MRTF sequence was cloned 
in frame into the Xho1–Apa1 sites of pcDNA3.1/Myc–His A. The entire 
construct was verified by sequencing. HA–MRTF-B was generated by engi-
neering a double-HA tag at the N terminus of MRTF-B using standard PCR 
methodology. The construct was verified by sequencing. B1 region deletion 
mutations of HA-tagged MRTF-B were generated using primer pairs com-
plementary to regions upstream and downstream of the specific deletion. 
Final constructs contained either a 7– (S279-P285; inclusive) or 13-aa de-
letion (S279-K291; inclusive). PCR reactions were performed using Pfu 
Turbo (Agilent Technologies). Resulting products were digested with Dpn1 
endonuclease,  transformed,  and  colonies  were  screened  by  restriction   
digest analysis or using PCR primers flanking the deletions. Selected clones 
were verified by sequencing. The pCGN-SRF plasmid encoding for the HA-
tagged human SRF was generated by R. Prywes (Johansen and Prywes, 
1993). Cells were transfected using FuGENE 6 or Lipofectamine 2000 re-
agents.  For  immunoprecipitation  of  heterologously  expressed  proteins, 
cells grown on 10-cm dishes were transfected with 5 µg Flag–MRTF-B and 
1 µg Myc-Smad3 vectors 48 h before the experiments. In triple transfection 
experiments, cells grown on 10-cm dishes were transfected with 4 µg Myc-
MRTF, 4 µg HA-SRF, and 6 µg Flag-Smad3 vectors for 24 h.397 Epithelial–myofibroblast transition • Masszi et al.
sis of variance (Tukey posthoc testing) as appropriate using Prism software 
(version 4.0; GraphPad Software, Inc.). P < 0.05 was accepted as signifi-
cant and is indicated with asterisks.
Online supplemental material
Fig. S1 shows the effect of TGF-, LCM, and their combination on the 
expression of a variety of cytoskeletal components regulated by CArG 
boxes. Using an alternative siRNA (Fig. 1 A), the results confirm that MRTF   
is  necessary  for  basal  expression  or  upregulation  of  these  proteins.   
Fig. S2 depicts key controls, showing that Smad3 binds MRTF and in-
dicates  that  Smad3  facilitates  the  nuclear  accumulation  of  MRTF.  On-
line  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.200906155/DC1.
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ChIP assay
Reagents for ChIP experiments were obtained from the EZ ChIP kit (Mil-
lipore), and assays were performed essentially as described by the manu-
facturer. LLC-PK1 cells were transfected with pig Smad3 or NR control 
siRNA  using  Lipofectamine  RNAiMAX  (Invitrogen).  Efficiency  of  down-
regulation  was  confirmed  by  Western  blotting  of  cell  lysates  prepared 
from matching plates to those used for ChIP assays. After down-regulation,   
cells were treated appropriately, cross-linked, lysed, and sheared by soni-
cation (450 Sonifier; Branson). DNA fragments were subjected to immuno-
precipitation  with  5  µg  rabbit  polyclonal  MRTF  antibody,  and  purified 
DNA was extracted from the recovered complexes. For negative controls, 
parallel experiments were performed using normal rabbit IgG as the   
immunoprecipitating antibody. Input and purified DNA from each sample 
were analyzed by SYBR green–based real-time PCR (IQ5 cycler; Bio-Rad 
Laboratories) using primers to amplify a CArG-containing region of the 
pig SMA promoter. Primer sequences were as follows: 5-AGTTTTGTGC-
TGAGGTCCCTATATG-3  and  5-TTCCCAAACAAGGAACAAAGA-3. 
Semi-qPCR was also performed by running products on a 3% agarose gel 
to detect the 79-bp amplicon.
Immunofluorescence microscopy
Cells grown on glass coverslips were fixed with 4% paraformaldehyde for 
30 min followed by intensive washing with PBS and incubation with 100 
mM glycine in PBS for 10 min. Cells were permeabilized in PBS containing 
1% Triton X-100 and 0.5% bovine serum albumin for 20 min, blocked in 
3% BSA in PBS for 1 h, and incubated with primary antibody for an addi-
tional 1 h. After a thorough wash, cells were incubated with the corre-
sponding fluorescently labeled secondary antibody with Cy3 dye (Jackson 
ImmunoResearch Laboratories). To visualize cotransfected Myc- and Flag-
tagged proteins simultaneously, samples were first incubated with anti-Flag 
(M2; Sigma-Aldrich) and Cy3-labeled anti–mouse antibodies and were 
stained with anti-Myc antibody (9E10) directly conjugated with FITC (Santa 
Cruz Biotechnology, Inc.). To visualize F-actin, fixed cells were incubated 
with rhodamine-labeled phalloidin (Invitrogen). For nuclear labeling, cells 
were stained with DAPI (Invitrogen), and coverslips were mounted on slides 
using fluorescent mounting medium (Dako). Samples were analyzed using 
a microscope (IX81; Olympus) with a UPlan S-Apo 60× 1.42 NA oil objec-
tive (Olympus) coupled to a camera (Evolution QEi Monochrome; Media 
Cybernetics) controlled by imaging software (QED InVivo; Media Cyber-
netics). Images were processed using ImagePro Plus software (3DS 5.1; 
Media Cybernetics) and Photoshop (CS4; Adobe). Modifications were re-
stricted exclusively to minor adjustments of brightness/contrast. MRTF dis-
tribution was quantified as described previously (Fan et al., 2007), except 
even stricter criteria were used to denote MRTF as nuclear. Staining inten-
sity was measured along a line across the cells, and the mean intensity in 
the cytoplasm and nucleus (verified by DAPI staining) was determined. 
MRTF localization was categorized as nuclear if the nuclear/cytoplasmic 
ratio was >1.5. This value corresponds to a clear nuclear accumulation as 
assessed by simple visual inspection (in unstimulated cells, the mean ratio 
is 0.6; i.e., there is a clear nuclear exclusion). Slides were evaluated by 
two independent observers, and at least 10 randomly selected fields (>200 
cells) were quantified for each condition in three experiments.
mRNA analysis
LLC-PK1 cells transfected with pig Smad3 or NR siRNA for 54 h were 
serum deprived for 3 h and treated with or without TGF- or LCM for 3 or 
6 h. In other experiments, nontransfected cells were exposed for 24 h to 
the four conditions of the two-hit scheme. After these treatments, RNA was 
extracted using an RNeasy kit (QIAGEN), and cDNA was synthesized 
from 1 µg total RNA using iScript reverse transcription (Bio-Rad Laborato-
ries). SYBR green–based real-time PCR was used to evaluate gene expres-
sion of PAI-1, SMA, and Smad3 using GAPDH as an endogenous control. 
Primer pairs designed against known pig sequences were used as follows:   
SMA, 5-TGTGACAATGGTTCTGGGCTCTGT-3 and 5-TTCGTCACCCAC-
GTAGCTGTCTTT-3; Smad3, 5-GCAGAACGTCAACACCAAGTGCAT-3 
and 5-ATTCACGCAGACCTCGTCCTTCTT-3; PAI-1, 5-CCACTGCTCT-
GGTGGTGAGA-3  and  5-GTTCTCGATGGTGGTGCTTT-3;  GAPDH, 
5-GCAAAGTGGACATGGTCGCCATCA-3 and 5-AGCTTCCCATTCT-
CAGCCTTGACT-3. Products from semi-qPCR were analyzed on 2% aga-
rose gels.
Statistical analysis
Data are presented as blots or images from at least three similar experi-
ments or as the means ± SEM for the number of experiments indicated. 
Statistical significance was determined by Student’s t test or one-way analy-JCB • VOLUME 188 • NUMBER 3 • 2010   398
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